Liaoning Chengda Biotechnology Co

Liaoning Chengda Biotechnology Co EBIT

The EBIT of Liaoning Chengda Biotechnology Co (688739.SS) as of Oct 18, 2026 is 196.98 M CNY. In the previous year, EBIT was 453.56 M CNY — a change of -56.57% (lower).

EBIT

196.98 MCNY

YoY

-56.57%

Last updated:

In 2025, Liaoning Chengda Biotechnology Co's EBIT was 196.98 M CNY, a -56.57% increase from the 453.56 M CNY EBIT recorded in the previous year.

The Liaoning Chengda Biotechnology Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2020
987.83 M CNY
Jan 1, 2021
1.03 B CNY
Jan 1, 2022
778.41 M CNY
Jan 1, 2023
592.74 M CNY
Jan 1, 2024
453.56 M CNY
Jan 1, 2025
196.98 M CNY
Jan 1, 2026 (e)
616.85 M CNY
Jan 1, 2027 (e)
0.00 CNY
The Liaoning Chengda Biotechnology Co EBIT history
YEAREBITYoY
est0.00CNY-100.00%
est616.85 MCNY+213.15%
196.98 MCNY-56.57%
453.56 MCNY-23.48%
592.74 MCNY-23.85%
778.41 MCNY-24.26%
1.03 BCNY+4.04%
987.83 MCNY+25.47%
787.33 MCNY+14.79%
685.90 MCNY+47.92%
463.70 MCNY-18.61%
569.70 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Liaoning Chengda Biotechnology Co Revenue

Liaoning Chengda Biotechnology Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
2.00 B CNY
987.83 M CNY
918.19 M CNY
Jan 1, 2021
2.09 B CNY
1.03 B CNY
892.49 M CNY
Jan 1, 2022
1.81 B CNY
778.41 M CNY
714.02 M CNY
Jan 1, 2023
1.75 B CNY
592.74 M CNY
465.92 M CNY
Jan 1, 2024
1.68 B CNY
453.56 M CNY
342.82 M CNY
Jan 1, 2025
1.39 B CNY
196.98 M CNY
131.79 M CNY
Jan 1, 2026 (e)
1.28 B CNY
616.85 M CNY
185.87 M CNY
Jan 1, 2027 (e)
1.40 B CNY
0.00 CNY
223.04 M CNY

Liaoning Chengda Biotechnology Co Margins

Liaoning Chengda Biotechnology Co stock margins

The Liaoning Chengda Biotechnology Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Liaoning Chengda Biotechnology Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Liaoning Chengda Biotechnology Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
86.25 %
49.50 %
46.01 %
Jan 1, 2021
89.85 %
49.22 %
42.74 %
Jan 1, 2022
87.11 %
42.89 %
39.34 %
Jan 1, 2023
83.65 %
33.87 %
26.62 %
Jan 1, 2024
82.94 %
27.06 %
20.45 %
Jan 1, 2025
79.37 %
14.17 %
9.48 %
Jan 1, 2026 (e)
79.37 %
48.30 %
14.55 %
Jan 1, 2027 (e)
79.37 %
0.00 %
15.89 %

Liaoning Chengda Biotechnology Co Stock analysis

What does Liaoning Chengda Biotechnology Co do? Liaoning Chengda Biotechnology Co., Ltd. is a prominent entity in the health care sector, specifically operating within the biotechnology industry. Headquartered in Shenyang, located in the Liaoning province of China, the company has established itself as a significant player in the development and commercialization of medical solutions. As of the latest available data, the organization employs a workforce of 1,663 full-time employees, reflecting its substantial operational scale and commitment to research and development activities. The company's primary business focus revolves around the research, development, manufacturing, and sale of vaccines, addressing critical public health needs through innovative biological products. The firm's product portfolio is centered on essential immunizations, including the rabies vaccine for human use and the freeze-dried rabies vaccine for human use. Additionally, the company produces vaccines targeting Japanese encephalitis, specifically offering the inactivated Japanese encephalitis vaccine for human use and the freeze-dried encephalitis inactivated vaccine. These products are marketed under two distinct brand names: Chengda Suda and Chengda Libao, which serve to differentiate the various offerings within the company's lineup. The strategic emphasis on these specific vaccines highlights the company's dedication to combating infectious diseases that pose significant risks to human health. Liaoning Chengda Biotechnology Co., Ltd. entered the public markets through an initial public offering on October 28, 2021, marking a significant milestone in its corporate history and providing it with greater access to capital for future growth and expansion. The company's official online presence can be found at http://www.cdbio.cn, where stakeholders and interested parties can access further information regarding its operations and developments. With its strong foundation in Shenyang and a dedicated team of professionals, the company continues to contribute to the global health care landscape by delivering high-quality vaccine solutions. The combination of its extensive employee base, specialized product range, and public market listing underscores its role as a key contributor to the biotechnology sector in China and beyond. Liaoning Chengda Biotechnology Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Liaoning Chengda Biotechnology Co's EBIT

Liaoning Chengda Biotechnology Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Liaoning Chengda Biotechnology Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Liaoning Chengda Biotechnology Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Liaoning Chengda Biotechnology Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Liaoning Chengda Biotechnology Co stock

EBIT of Liaoning Chengda Biotechnology Co is 196.98 M CNY in 2025.

EBIT of Liaoning Chengda Biotechnology Co changed from 453.56 M CNY to 196.98 M CNY, representing a -56.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Liaoning Chengda Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Liaoning Chengda Biotechnology Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Liaoning Chengda Biotechnology Co

All Key Metrics — Liaoning Chengda Biotechnology Co